Exagen Inc (XGN)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
SERVICES-MEDICAL LABORATORIES
CEO:
Mr. Fortunato Ron Rocca
Employees:
1261 LIBERTY WAY, VISTA, CA 92081
(760) 560-1501

Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Data derived from most recent annual or quarterly report
Market Cap 91.196 Million Shares Outstanding16.256 Million Avg 30-day Volume 104.071 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.86
Price to Revenue2.8364 Debt to Equity0.3631 EBITDA-26.873 Million
Price to Book Value1.7917 Operating Margin-58.576899999999995 Enterprise Value74.349 Million
Current Ratio8.721 EPS Growth-0.324 Quick Ratio8.47
1 Yr BETA 1.1521 52-week High/Low 15.41 / 4.15 Profit Margin-64.2623
Operating Cash Flow Growth-62.5108 Altman Z-Score-0.1865 Free Cash Flow to Firm -23.497 Million
Earnings Report2022-08-08
View SEC Filings from XGN instead.

View recent insider trading info

Funds Holding XGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-22:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-10:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-25:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2021-08-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2021-08-09:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    TULLIS JAMES L L

    • Director
    • 10% Owner
    9,000 2022-06-16 3

    NOVA TINA SUSAN

    • Director
    9,000 2022-06-16 1

    PALLARES EBETUEL

    • Director
    9,000 2022-06-16 1

    BIRK BRIAN

    • Director
    9,000 2022-06-16 1

    JOHNSON WENDY S.

    • Director
    9,000 2022-06-16 2

    HOOKER ANA

    • Director
    9,000 2022-06-16 3

    STOKES FRANK

    • Director
    9,000 2022-06-16 1

    ROCCA FORTUNATO R. PRESIDENT AND CEO

    • Officer
    • Director
    120,678 2022-03-01 2

    ADAWI KAMAL CFO AND CORPORATE SECRETARY

    • Officer
    97,759 2022-03-01 2

    ZACK DEBRA CHIEF MEDICAL OFFICER

    • Officer
    84,259 2022-03-01 2

    HAZELTINE MARK CHIEF OPERATING OFFICER

    • Officer
    99,693 2022-03-01 2

    ROBERTSON BRUCE C

    • Director
    9,000 2021-06-17 0

    HUNT HOLDINGS LIMITED PARTNERSHIP

    HUNTVEST, LLC

    HUNT GUARANTY INC.

    HUNT WOODY L

    • 10% Owner
    1,261,324 2021-01-22 0

    NMSIC CO-INVESTMENT FUND, L.P.

    SUN MOUNTAIN CAPITAL PARTNERS LLC

    • 10% Owner
    2,308,958 2020-12-15 0

    ELLIOTT JEFFREY THOMAS

    • Director
    0 2020-06-18 0

    BURRELL CHET

    • Director
    0 2020-06-18 0

    TULLIS DICKERSON CAPITAL FOCUS III, L.P.

    TULLIS GROWTH FUND, L.P.

    TULLIS GROWTH FUND II, L.P.

    TULLIS DICKERSON PARTNERS III, L.L.C.

    • 10% Owner
    1,625,165 2020-03-20 0

    H.I.G. BIO-EXAGEN, L.P.

    H.I.G.-GPII, INC.

    TAMER ANTHONY

    MNAYMNEH SAMI

    • 10% Owner
    1,696,252 2019-09-23 0

    NMSIC CO-INVESTMENT FUND, L.P.

    NMSIC FOCUSED LLC

    SUN MOUNTAIN CAPITAL PARTNERS LLC

    • 10% Owner
    2,560,362 2019-09-19 0

    DERVIEUX THIERRY CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2019-09-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    TULLIS JAMES L L - Director - > 10% Owner

    2022-06-21 08:33:09 -0400 2022-06-16 A 9,000 a 9,000 direct

    HOOKER ANA - Director

    2022-06-21 08:32:51 -0400 2022-06-16 A 9,000 a 9,000 direct

    BIRK BRIAN - Director

    2022-06-21 08:32:33 -0400 2022-06-16 A 9,000 a 9,000 direct

    STOKES FRANK - Director

    2022-06-21 08:32:15 -0400 2022-06-16 A 9,000 a 9,000 direct

    JOHNSON WENDY S. - Director

    2022-06-21 08:34:01 -0400 2022-06-16 A 9,000 a 9,000 direct

    PALLARES EBETUEL - Director

    2022-06-21 08:33:42 -0400 2022-06-16 A 9,000 a 9,000 direct

    NOVA TINA SUSAN - Director

    2022-06-21 08:33:26 -0400 2022-06-16 A 9,000 a 9,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    EXAGEN INC XGN 2022-06-30 22:15:03 UTC -0.3848 1.9548 5000
    EXAGEN INC XGN 2022-06-30 21:45:03 UTC -0.3848 1.9548 5000
    EXAGEN INC XGN 2022-06-30 21:15:03 UTC -0.3848 1.9548 5000
    EXAGEN INC XGN 2022-06-30 20:45:03 UTC -0.4184 1.9884 5000
    EXAGEN INC XGN 2022-06-30 20:15:04 UTC -0.4184 1.9884 5000
    EXAGEN INC XGN 2022-06-30 19:45:03 UTC -0.4184 1.9884 5000
    EXAGEN INC XGN 2022-06-30 19:15:03 UTC -0.4184 1.9884 5000
    EXAGEN INC XGN 2022-06-30 18:45:04 UTC -0.3707 1.9407 5000
    EXAGEN INC XGN 2022-06-30 18:15:04 UTC -0.3707 1.9407 5000
    EXAGEN INC XGN 2022-06-30 17:45:03 UTC -0.3707 1.9407 5000
    EXAGEN INC XGN 2022-06-30 17:15:03 UTC -0.3707 1.9407 5000
    EXAGEN INC XGN 2022-06-30 16:45:04 UTC -0.329 1.899 5000
    EXAGEN INC XGN 2022-06-30 16:15:03 UTC -0.329 1.899 5000
    EXAGEN INC XGN 2022-06-30 15:45:03 UTC -0.329 1.899 5000
    EXAGEN INC XGN 2022-06-30 15:15:03 UTC -0.329 1.899 5000
    EXAGEN INC XGN 2022-06-30 14:45:03 UTC -0.329 1.899 5000
    EXAGEN INC XGN 2022-06-30 14:15:03 UTC -0.329 1.899 5000
    EXAGEN INC XGN 2022-06-30 13:45:03 UTC -1.0297 2.5997 5000
    EXAGEN INC XGN 2022-06-30 13:15:03 UTC -1.0297 2.5997 5000
    EXAGEN INC XGN 2022-06-30 12:45:03 UTC -1.0297 2.5997 5000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments